Nilotinib Capsule
Product Images NDC 73190-033

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Nilotinib (NDC 73190-033). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (033 11)

Packaging label for Nilotinib Capsules 150 mg by AvKARE. The label indicates oral capsules with 28 capsules per package. It includes instructions for use on opening and closing the kit, dosage warnings about taking on an empty stomach, and displaying the NDC code. The label prominently displays the product name and strength on multiple panels.*

FDA Label Image

1 (033 12)

Nilotinib Capsules 150 mg oral capsules label by AvKARE shows the proprietary and generic name, strength per capsule, and a medication guide instruction to take on an empty stomach. The label states packaging contents as 4 individual blister packs containing 28 capsules each, and includes the NDC number 73190-033-12.*

FDA Label Image

1 (034 11)

Packaging label for nilotinib capsules 200 mg by AvKARE. The label indicates oral capsule dosage form and includes instructions for use, such as how to open and close the kit. It specifies 28 capsules per package and notes pharmacist dispensing instructions and warnings about taking the medication on an empty stomach.*

FDA Label Image

1 (034 12)

Label for AvKARE Nilotinib Capsules 200 mg oral capsules. The label includes dosage administration instructions for an empty stomach and package content information indicating four individual blister packs containing 28 capsules each.*

FDA Label Image

Nilotinib-cap-fig-1 (Nilotinib Cap Fig 1)

A Kaplan-Meier survival curve showing treatment-free survival percentage over time since treatment-free remission (TFR) in weeks. The graph includes a solid survival curve line with dashed confidence interval bounds and marks censored observations with vertical ticks. Numbers at risk, events, and censored counts are detailed below the x-axis.*

FDA Label Image

Nilotinib-cap-fig-2 (Nilotinib Cap Fig 2)

Kaplan-Meier survival curve illustrating treatment-free survival (TFR) over time in weeks for a patient cohort. The graph includes a survival percentage on the y-axis and time since TFR in weeks on the x-axis, with confidence intervals and censoring marks shown alongside event counts and number of patients at risk.*

FDA Label Image

Nilotinib-cap-structure (Nilotinib Cap Structure)

Chemical structure of nilotinib depicting its molecular arrangement, including rings, nitrogen atoms, trifluoromethyl group (CF3), and associated hydrochloride hydrate (HCl 1.5H2O).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.